BRIM Biotechnology, Inc. (6885) Stock Price & Analysis
6885 Stock Chart & Stats
- Day’s Range
- TWD 23.60 - TWD 26.75
- 52-Week Range
- TWD 20.05 - TWD 34.65
- Previous Close
- TWD 25.45
- Volume
- N/A
- Average Volume (3M)
- 873.87K
- Market Cap
- TWD 3.55B
- Enterprise Value
- TWD 1.92B
- Total Cash (Recent Filing)
- N/A
- Total Debt (Recent Filing)
- N/A
- Price to Earnings (P/E)
- ―
- Beta
- 0.27
- Next Earnings
- Nov 17, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
6885 FAQ
What was BRIM Biotechnology, Inc.’s price range in the past 12 months?
What is BRIM Biotechnology, Inc.’s market cap?
When is BRIM Biotechnology, Inc.’s upcoming earnings report date?
How were BRIM Biotechnology, Inc.’s earnings last quarter?
Is BRIM Biotechnology, Inc. overvalued?
Does BRIM Biotechnology, Inc. pay dividends?
What is BRIM Biotechnology, Inc.’s EPS estimate?
How many shares outstanding does BRIM Biotechnology, Inc. have?
What happened to BRIM Biotechnology, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of BRIM Biotechnology, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
BRIM Biotechnology, Inc.
BRIM Biotechnology, Inc. engages in the research and development of drugs and therapies to combat and cure diseases in Taiwan. The company's lead product candidate is BRM421, a neurotrophic peptide which has completed a Phase 3 clinical trial for the treatment of dry eye disease. It is also developing BRM424, a treatment option that has completed Phase 1 clinical trial for neurotrophic keratitis; BRM411, a dual target inhibitor, which has completed Phase 2 clinical trial for the treatment of glaucoma; BRM412, an anti-angiogenic eye drop that has completed Phase 2 clinical trial to treat wet age-related macular degeneration; and BRM521, a PEDF-derived short peptide that is in pre-clinical trial to relieve and repair tissue damage caused by osteoarthritis. BRIM Biotechnology, Inc. was founded in 2013 and is based in Taipei, Taiwan.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Wen Qi Xu
- Employees
- 32
- Website
- www.brimbiotech.com
- Address
- No.1, Alley 30, Taipei, TP, 11492, TW
BRIM Biotechnology, Inc. (6885) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 4 | 10 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 4 | 0 | 8 |

